Alcon, a global leader in eye care introduces PRECISION1, its next-generation daily disposable contact lenses, designed to deliver up to 16 hours of comfort. PRECISION1– India’s 1st SMARTSURFACE lens ...

In the U.S. market, we currently have three newer multifocal IOLs approved for use: the Alcon Clareon PanOptix Pro, the ...

Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first FDA approval for a prescription drug, scoring a nod for dry eye disease ...

Alcon Inc. has received its first Food and Drug Administration approval since its spinoff from Swiss medical giant Novartis in 2019.

FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.

GENEVA, May 28, 2025--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease ...

FDA approves Alcon's TRYPTYR for effective treatment of Dry Eye Disease, offering a new solution for this common eye condition.

Analysts at BTIG have reiterated a Buy rating for Alcon, maintaining a $99 price target, while Stifel analysts also upheld a Buy rating with a $100 price target, focusing on TRYPTYR’s unique ...

Alcon Inc. (NYSE:ALC) has announced that the U.S. Food and Drug Administration (FDA) has approved TRYPTYR (acoltremon ophthalmic solution) 0.003% for the treatment of signs and symptoms of Dry Eye ...

In premium lenses, the statistic is even more impressive, with one out of two ATIOLs being an Alcon product. The company’s flagship lenses, Vivity and PanOptix, continue to lead the category in ...